Alnylam Pharmaceuticals (ALNY) Earnings Analysis
Alnylam Pharmaceuticals (ALNY) next reports earnings on 2026-07-30, consensus EPS 1.63 USD. Last quarter (2026-04-30) it beat with EPS 1.51 USD vs 0.872 USD est (+73.2%). It has beaten estimates in 7/8 recent quarters (88%). Trailing P/E 61.24.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ALNY next report earnings?
| Next earnings date | 2026-07-30 |
|---|---|
| Consensus EPS estimate | 1.63 USD |
| Revenue estimate | 1.32B |
ALNY earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | 1.51 USD | 0.872 USD | +73.2% | Beat |
| 2026-02-12 | 0.82 USD | 1.16 USD | -29.3% | Miss |
| 2025-10-30 | 2.9 USD | 0.561 USD | +416.9% | Beat |
| 2025-07-31 | 0.32 USD | -0.54371 USD | +158.9% | Beat |
| 2025-05-01 | -0.01 USD | -0.89002 USD | +98.9% | Beat |
| 2025-02-13 | 0.06 USD | -0.62 USD | +109.7% | Beat |
| 2024-10-31 | -0.5 USD | -0.91663 USD | +45.5% | Beat |
| 2024-08-01 | 0.56 USD | -1.07 USD | +152.3% | Beat |
Beat rate: 7/8 (88%) over reported quarters with consensus data.
ALNY valuation and analyst view
| Trailing P/E | 61.24 |
|---|---|
| Trailing EPS | 4.343 USD |
| Price / book | 32.99 |
| Dividend yield | 0.00% |
| Market cap | 35.31B |
| Analyst consensus | Buy (39 buy / 12 hold / 1 sell) |
| Avg price target | 435.71 USD |
Related research pages
Frequently asked questions
When is Alnylam Pharmaceuticals (ALNY)'s next earnings date?
Alnylam Pharmaceuticals is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 1.63 USD and revenue estimate of 1.32B.
Did ALNY beat earnings last quarter?
In its 2026-04-30 report, ALNY posted EPS of 1.51 USD versus a 0.872 USD estimate — a beat of 73.2%.
What is ALNY's earnings track record?
Over the last 8 reported quarters with consensus data, ALNY beat estimates 7 times (88%).
What is ALNY's current P/E ratio and EPS?
ALNY trades at a trailing P/E of 61.24 on trailing EPS of 4.343471815671254 USD.
What do analysts rate ALNY?
Analyst consensus is "Buy" across 52 ratings (0 strong buy, 39 buy, 12 hold, 1 sell, 0 strong sell). Average 12-month price target: 435.71 USD.